Moringa Pharmaceuticals

What Moringa Pharmaceuticals does

Moringa Pharmaceuticals Pvt Ltd is a Pakistan-based pharmaceutical manufacturer and wholly-owned subsidiary of Pharmagen Pvt Ltd, the country's leading producer of Active Pharmaceutical Ingredients (API). The company was acquired by Pharmagen in 2017 and operates a purpose-built cGMP-compliant manufacturing facility in Lahore spanning 36,500 square feet, equipped with 16 HVAC systems, a microbiological lab, and a Double Pass Reverse Osmosis water purification system producing 500 liters of purified water per hour. Production commenced in September 2018 with stated monthly capacity of 360,000 blister tablets, 1.2 million capsules, 1 million syrup units, and 500,000 dry powder suspensions.

The company manufactures and markets a portfolio of generic prescription drugs across six therapeutic categories: alimentary tract products (proton pump inhibitors Gem-Ton, Safpep, Kurazole; laxative Moringa-Lact; prokinetic Gasidon), systemic antibacterials (fluoroquinolones Ringacip, Levo-M, Myriva; macrolides Azydec, Clarimor), respiratory (Montemore/Montelukast), anti-fungal (Amphozole/Fluconazole), blood-forming agents (Feromor-S), and musculoskeletal (Safkam/Piroxicam). Sales occur through traditional pharmaceutical distribution channels — wholesalers plus direct hospital and clinic supply — targeting healthcare providers, rural Pakistani populations, and multinational pharmaceutical companies seeking quality manufacturing partners. GTM is sales-led via a professional marketing team with stated six decades of combined experience.

Revenue figures and pricing are not publicly disclosed. Moringa holds GMP certification from DRAP (October 2019), ISO 9001:2015 (October 2019), GS1 Pakistan serialization licensing (March 2018), and was the first company in Punjab and third in Pakistan to achieve Halal Healthcare Products certification under PSQCA standard 5442:2019 (January 2020). The company operates CSR initiatives including the Sehat Clinic in Kot Ishaq, Hafizabad (partnered with The Diagnostic Centre) and educational support through the M.H. Sufi Foundation (600 students across 15 schools).

Name

Moringa Pharmaceuticals

Legal name

Moringa Pharmaceuticals Pvt Ltd

Website

https://moringapharmaceuticals.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Moringa Pharmaceuticals is a Pakistan-based cGMP-compliant pharmaceutical manufacturer and wholly-owned subsidiary of Pharmagen Pvt Ltd, producing generic prescription drugs across six therapeutic categories for healthcare providers, rural populations, and multinational customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Finished dosage forms
• CGMP production
• Halal certified drugs

Headquarters

HQ city

Lahore

HQ country

Pakistan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Personnel

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including tablets, capsules, syrups, and dry powder suspensions across therapeutic categories including alimentary tract, systemic antibacterial, musculoskeletal, respiratory, anti-fungal, and blood forming agents

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Moringa Pharmaceuticals manufactures and supplies finished pharmaceutical dosage forms including tablets, capsules, syrups, and dry powder suspensions across six therapeutic categories (alimentary tract, systemic antibacterials, musculoskeletal, respiratory, anti-fungal, and blood forming agents). The company operates a cGMP-compliant production facility in Lahore, Pakistan, with monthly capacities of 360,000 tablets, 1.2 million capsules, 1 million syrups, and 500,000 dry powder suspensions, distributing through pharmaceutical wholesalers, distributors, hospitals, and clinics across Pakistan.

Product overview

Moringa Pharmaceuticals is a cGMP-compliant pharmaceutical drug manufacturer based in Pakistan, producing and marketing prescription medications across six therapeutic categories. The product portfolio includes: Alimentary Tract products (anti-ulcerants Gem-Ton/Esomeprazole, Safpep/Omeprazole, Kurazole/Lansoprazole; laxative Moringa-Lact/Lactulose; prokinetic Gasidon/Domperidone); Systemic Antibacterials (fluoroquinolones Ringacip/Ciprofloxacin, Levo-M/Levofloxacin, Myriva/Moxifloxacin; macrolides Azydec/Azithromycin, Clarimor/Clarithromycin); Respiratory Tract (Montemore/Montelukast); Anti-Fungal (Amphozole/Fluconazole); Blood Forming Agents (Feromor-S/Iron Protein Succinylate); and Musculoskeletal (Safkam/Piroxicam). The company operates as a subsidiary of Pharmagen Pvt Ltd, producing affordable pharmaceuticals with a focus on rural accessibility.

Differentiator

Problem solved

Functional benefit

Products and services

• Gem-Ton (Esomeprazole 20mg/40mg) Gem-Ton is a proton pump inhibitor containing Esomeprazole in 20mg and 40mg strengths, used to treat gastric acid-related disorders including GERD, peptic ulcers, and Zollinger-Ellison syndrome. Sold to healthcare providers and pharmacies across Pakistan.
• Safpep (Omeprazole 20mg/40mg) Safpep is a proton pump inhibitor containing Omeprazole in 20mg and 40mg strengths, used to treat gastric acid-related disorders including duodenal and gastric ulcers, reflux oesophagitis, symptomatic GERD, and NSAID-associated gastric damage.
• Kurazole (Lansoprazole 30mg) Kurazole is a proton pump inhibitor containing Lansoprazole 30mg, used to treat duodenal and gastric ulcers, reflux oesophagitis, and H. pylori eradication in combination therapy.
• Moringa-Lact (Lactulose 3.35g/5ml) Moringa-Lact is a laxative containing Lactulose 3.35 g/5 ml, used for treatment of constipation and hepatic encephalopathy in adults and children.
• Gasidon (Domperidone 1mg/ml, 60ml and 120ml) Gasidon is a prokinetic agent containing Domperidone 1mg/ml in 60ml and 120ml oral suspension presentations, used as an antiemetic, gastroprokinetic, and galactagogue.
• Ringacip (Ciprofloxacin tablets 250mg/500mg and oral suspension 125mg/5ml and 250mg/5ml) Ringacip is a second-generation fluoroquinolone antibiotic containing Ciprofloxacin as HCL, available in 250mg and 500mg tablets and 125mg/5ml and 250mg/5ml oral suspensions (including pediatric formulations), used to treat bacterial infections of the respiratory tract, urinary tract, and gastrointestinal tract.
• Levo-M (Levofloxacin 250mg/500mg) Levo-M is a third-generation fluoroquinolone antibiotic containing Levofloxacin as hemihydrate in 250mg and 500mg strengths, used to treat community-acquired pneumonia, complicated skin infections, chronic bacterial prostatitis, and urinary tract infections.
• Myriva (Moxifloxacin 400mg) Myriva is a fourth-generation fluoroquinolone containing Moxifloxacin as HCL 400mg with expanded activity against gram-positive bacteria and atypical pathogens, used for community-acquired pneumonia and skin infections.
• Azydec (Azithromycin 250mg capsules and 200mg/5ml suspension) Azydec is a macrolide antibiotic containing Azithromycin as Dihydrate, available in 250mg capsules and 200mg/5ml oral suspension (for pediatric use), used to treat respiratory infections, skin infections, and sexually transmitted infections.
• Clarimor (Clarithromycin 250mg/500mg tablets and 125mg/5ml suspension) Clarimor is a semisynthetic macrolide antibiotic containing Clarithromycin, available in 250mg and 500mg tablets and 125mg/5ml oral suspension for pediatric use, used to treat respiratory infections, skin infections, and H. pylori eradication.
• Montemore (Montelukast 10mg and 5mg chewable) Montemore is a selective leukotriene receptor antagonist containing Montelukast as sodium, available in 10mg tablets and 5mg chewable tablets (for pediatric patients aged 6-14 years), used for prophylaxis and chronic treatment of asthma and relief of seasonal allergic rhinitis.
• Amphozole (Fluconazole 150mg) Amphozole is a triazole fungistatic agent containing Fluconazole 150mg, used in the treatment of systemic and superficial fungal infections including genital candidiasis and dermatomycosis.
• Feromor-S (Iron Protein Succinylate 800mg/15ml) Feromor-S is an oral iron preparation containing Iron Protein Succinylate 800mg/15ml, a ferric iron complex used to treat iron deficiency anemia in adults and children.
• Safkam (Piroxicam 20mg) Safkam is a non-steroidal anti-inflammatory drug (NSAID) containing Piroxicam as beta-cyclodextrin 20mg, used to treat pain and inflammation.

Quantifiable outcome

• First Halal certified pharmaceutical company in Punjab, Pakistan (third in Pakistan)
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• The Diagnostic Centre (Lahore)minorStrategic or Co-development Partner · 22 February 2017Collaboration for full diagnostic facilities at Sehat Clinic in Kot Ishaq, Hafizabad. The Diagnostic Centre provides diagnostic support services for the CSR healthcare initiative serving rural communities.
• M.H. Sufi FoundationminorStrategic or Co-development PartnerNon-profit organization established in 1994 promoting quality education in rural Pakistan. Parvez Sufi, son of late Mohammad Hussain Sufi, founded the project. Moringa supports this initiative as part of CSR activities.

Scale indicators5 records

Recent moves6 records

Expansion highlights2 records

Broad incumbents

• ICI Pakistan (Pharma): Diversified Pakistani conglomerate with a pharmaceuticals business covering generics and branded products. Comparable as a larger incumbent Pakistani pharma player with broader portfolio and stronger brand equity than Moringa.
• Pharmagen Pvt Ltd: Parent company and Pakistan's leading Active Pharmaceutical Ingredient producer serving 215+ customers. Directly comparable as the upstream API supplier feeding Moringa and as the broader pharma group whose strategy sets Moringa's trajectory.

Direct peers

• Highnoon Laboratories: Established Pakistani pharmaceutical manufacturer with a diversified generic portfolio and strong domestic distribution. Comparable as a multi-category generic FDF producer serving Pakistani healthcare providers.
• Hilton Pharma: Pakistan-based pharmaceutical manufacturer producing generics across multiple therapeutic areas with national distribution. Comparable mid-tier domestic generic FDF competitor with similar therapeutic-category overlap.
• The Searle Company: Major Pakistani pharmaceutical manufacturer with a broad generic and branded portfolio across multiple therapeutic categories. Directly comparable in product breadth, dosage forms, and Pakistan-focused sales coverage.
• Ferozsons Laboratories: Listed Pakistani pharmaceutical manufacturer with generic and specialty products and active export operations. Comparable as a domestic generic FDF peer with multi-therapy portfolio and cGMP manufacturing.
• Sami Pharmaceuticals: Pakistani generic pharmaceutical company focused on affordable medicines across multiple therapeutic categories. Similar scale and generic FDF positioning to Moringa within the domestic market.
• Barrett Hodgson Pakistan: Pakistan-based pharmaceutical manufacturer producing generics across multiple therapeutic categories. Comparable generic FDF competitor with overlapping product types and Pakistan-centric distribution.
• AGP Limited: Pakistani pharmaceutical company with a broad generic portfolio and significant national distribution network. Directly comparable in therapeutic coverage and Pakistani retail/institutional channels.
• Getz Pharma: One of Pakistan's largest generic pharmaceutical manufacturers with a broad multi-therapeutic portfolio and significant domestic and export presence. Comparable as a generic FDF producer serving the same hospital, pharmacy, and physician channels in Pakistan.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moringa Pharmaceuticals